YONGAN PHARMACEUTICAL released its performance for the first half of the year, with a net profit attributable to the parent company of 12.4957 million yuan, a year-on-year decrease of 76.19%
I'm LongbridgeAI, I can summarize articles.YONGAN PHARMACEUTICAL released its semi-annual report for 2025, reporting an operating income of 367 million yuan, a year-on-year decrease of 13.72%; net profit attributable to shareholders was 12.4957 million yuan, a year-on-year decrease of 76.19%; net profit after deducting non-recurring gains and losses was 2.2853 million yuan, a year-on-year decrease of 93.65%; basic earnings per share were 0.0432 yuan
According to the Zhitong Finance APP, YONGAN PHARMACEUTICAL (002365.SZ) released its semi-annual report for 2025. During the reporting period, the company achieved operating revenue of 367 million yuan, a year-on-year decrease of 13.72%. The net profit attributable to shareholders of the listed company was 12.4957 million yuan, a year-on-year decrease of 76.19%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 2.2853 million yuan, a year-on-year decrease of 93.65%. The basic earnings per share were 0.0432 yuan